ST. PETERSBURG, Fla., Jan. 9, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced a proposed novel therapy for the treatment of the currently untreatable neurological condition Neurofibromatosis. The key to this breakthrough is the targeted application of the Felder Doctrine™, which calls for "physically removing the pathophysiologic basis of the disease." The painful and often fatal disease Neurofibromatosis, which is characterized by the growth of tumors around nerves, appears in three classifications, with type 1 Neurofibromatosis affecting about 1 in 3,500 individuals worldwide. By processing the blood feeding the neurofibromas and by physically removing inflammatory cytokines and other molecular compounds responsible for the etiology of the disease, Premier Biomedical's Chairman of the Scientific Advisory Board Mitchell S. Felder, M.D., a board certified attending neurologist, believes that it is possible to stop the progression of the disease. Premier Biomedical's CEO William A. Hartman emphasized, "At present, this is a hopeless disease, and to date, there has not been even a possibility of treatment. By applying for a provisional patent application, we are making the first step in our attempt to beat Neurofibromatosis. This potential breakthrough follows our other recent successes in applying the Felder Doctrine to cancer, clinical depression and suicidal ideation." The news of this announcement follows Premier Biomedicals other recent applications of the Felder Doctrine, which include: killing a cancer tumor in a test tube within 24 hours by simply processing its environment, removing a specified cancer-related Interleukin from a heterogeneous mixture at a picogram (trillionth of a gram) level of accuracy, and successfully removing the majority of target antigens associated with clinical depression and suicidal ideation from a heterogeneous mixture, also at a picogram level of accuracy. About Premier Biomedical, Inc. Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/ Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI."www.premierbiomedicalinc.comSafe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.